Resilience in purpose and openess in strategic direction are key dual features in the DNA of strong biotechs which succeed in the long run and live to survive the roller coaster ride that is oncology R&D.
Setbacks are to be expected, but what matters more is not that they happen, but the mettle and toughness to deal with them over time.
There is no doubt Clovis Oncology encountered a major setback with the abandonment of rociletinib in lung cancer, while the rise of PARP inhibitors meant they were well placed with the rucaparib development.
Beyond these events, what next?
It’s time to take a bigger picture look at what’s happening with the pipeline and where they might be heading since there could be some surprises in store…